Watch and wait after immune therapy for returning nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests if careful monitoring after a combination of immunotherapy and chemotherapy is a safe and effective approach for patients whose nasopharyngeal cancer has come back but not spread to other parts of the body. It aims to reduce unnecessary treatment while keeping the cancer under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been recently diagnosed with nasopharyngeal cancer that has come back in the same area (not spread to distant organs).
- You have not yet had any treatment for this cancer.
- You will be receiving immunotherapy as part of your treatment.
- You have at least one tumor that can be measured on scans.
- You do not have another active cancer (except certain low-risk skin or early-stage cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether adding chemo-immunotherapy after surgery is better than surgery alone for patients whose nasopharyngeal cancer has returned but is still in early stages. It may help prevent the cancer from coming back again.
This trial studies toripalimab (an immunotherapy that helps your immune system attack cancer) for nasopharyngeal cancer that has come back locally. It may help shrink or control the returning tumor and improve outcomes for people who meet the safety and lab requirements.
This trial tests a combination of high and low dose radiation plus an immunotherapy drug (PD-1 inhibitor) for people whose nasopharyngeal cancer has come back after previous treatment. The goal is to see if this approach can be more effective while reducing side effects.
This trial tests whether maintenance immunotherapy (PD-1 inhibitor) followed by delayed salvage radiation therapy can help keep your cancer under control after you have already responded to initial chemo-immunotherapy. It is for people with recurrent nasopharyngeal carcinoma that has come back in the nose or neck area, but has not spread to distant organs.
This trial tests a combination of low-dose radiation and immunotherapy (drugs that help your immune system fight cancer) for people with nasopharyngeal cancer that has spread to other parts of the body and who cannot receive chemotherapy. The goal is to see if this treatment can help control the cancer and improve outcomes.
This trial studies whether adding an anti–PD-1 immunotherapy to standard chemoradiotherapy can control nasopharyngeal cancer that has come back in the local area. It may help patients live longer or have the cancer respond better compared with chemoradiotherapy alone.
Hear when a new Recurrent Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.